Show simple item record

dc.contributor.author Λουκάς, Ιωάννης el
dc.contributor.author Καρίκας, Γεώργιος-Αλβέρτος el
dc.contributor.author Γαζούλη, Μαρία el
dc.contributor.author Καλαμπαλίκης, Παναγιώτης el
dc.contributor.author Χατζής, Τάσος el
dc.date.accessioned 2015-05-08T22:04:04Z
dc.date.available 2015-05-08T22:04:04Z
dc.date.issued 2015-05-09
dc.identifier.uri http://hdl.handle.net/11400/10015
dc.rights Αναφορά Δημιουργού-Μη Εμπορική Χρήση-Όχι Παράγωγα Έργα 3.0 Ηνωμένες Πολιτείες *
dc.rights.uri http://creativecommons.org/licenses/by-nc-nd/3.0/us/ *
dc.source http://link.springer.com/article/10.1023%2FB%3APHAM.0000048198.56873.d8 en
dc.subject βρέφη
dc.subject φαρμακοκινητική
dc.subject προσομοίωση
dc.subject τειχοπλανινο
dc.subject infants
dc.subject Pharmacokinetics
dc.subject simulation
dc.subject teicoplanin
dc.title Pharmacokinetics of teicoplanin in an ICU population of children and infants en
heal.type journalArticle
heal.classification Φαρμακευτική
heal.classification Παιδιά
heal.classification Pharmacy
heal.classification Children
heal.classificationURI **N/A**-Φαρμακευτική
heal.classificationURI **N/A**-Παιδιά
heal.classificationURI http://id.loc.gov/authorities/subjects/sh85100603
heal.classificationURI http://id.loc.gov/authorities/subjects/sh85023418
heal.keywordURI http://id.loc.gov/authorities/subjects/sh00006940
heal.contributorName Μαχαίρας, Παναγιώτης el
heal.identifier.secondary ISSN: 1573-904X
heal.language en
heal.access campus
heal.recordProvider Τεχνολογικό Εκπαιδευτικό Ίδρυμα Αθήνας. Σχολή Επαγγελμάτων Υγείας και Πρόνοιας. Τμήμα Ιατρικών Εργαστηρίων el
heal.publicationDate 2004-11
heal.bibliographicCitation Lukas, J.C., Karikas, G., Gazouli, M., Kalabalikis, P., Hatzis, T. et al. (2004) Pharmacokinetics of teicoplanin in an ICU population of children and infants. Pharmaceutical Research. [Online] 21 (11). pp.2064-2071. Available from: http://link.springer.com [Accessed 08/05/2015] en
heal.abstract Purpose. Better dosing is needed for antibiotics, including teicoplanin (TEI), to prevent emergence of resistant bacterial strains. Here, we assess the TEI pharmacokinetics (PK) related to a 10 mg/l minimum inhibitory concentration (MIC) target in ICU children (4 to 120 months; n = 20) with gram+ infections. Methods. Standard administration of TEI was with three 10 mg/kg Q12h, loading infusions, and maintainance with 10 mg/kg or 15 mg/kg Q24h. During maintenance, 9 samples (3/day) were collected per patient and the PK analyzed with Nonlinear Mixed Effects Model (NONMEM). Results. Thirty-five percent of concentrations in older children (≥2 months) vs. 8% in younger infants (<12 months) were below the target MIC. The global bicompartmental population PK parameters were [mean (interindividual CV%)] CL = 0.23 l/h [72%], V = 3.16 l [58%], k12 = 0.23 h−1, and k21 = 0.04 h−1. Two PK subpopulations were identified. The older children had CL = 0.29 [23%] l/h, V = 3.9 l and the younger infants, CL = 0.09 [37%] l/h, V = 1.05 l. Residual error was reduced from 52% to around 30% in the final models. Conclusions. Older children in the ICU may require relatively higher doses of teicoplanin. However, a study in a larger population is needed. en
heal.journalName Pharmaceutical Research en
heal.journalType peer-reviewed
heal.fullTextAvailability true


Files in this item

  • Name: teico.pdf
    Size: 219.3Kb
    Format: PDF

The following license files are associated with this item:

Show simple item record

Αναφορά Δημιουργού-Μη Εμπορική Χρήση-Όχι Παράγωγα Έργα 3.0 Ηνωμένες Πολιτείες Except where otherwise noted, this item's license is described as Αναφορά Δημιουργού-Μη Εμπορική Χρήση-Όχι Παράγωγα Έργα 3.0 Ηνωμένες Πολιτείες